{
  "id": 19245875,
  "title": "Ionis: 3 Key Takeaways for Long-Term Investors",
  "url": "https://urgent.news/2026/11/09/ionis-3-key-takeaways-for-long-term-investors",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T23:53:38.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/earnings/takeaways/2026/11/09/ionis-3-key-takeaways-for-long-term-investors/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Ionis Pharmaceuticals (IONS) issued a lowered revenue forecast on its third-quarter 2026 earnings call on November 9, 2026. The company expects its full-year revenue for 2026 to be around $50 million, reflecting a slower-than-anticipated launch for TRYNGOLZA. TRYNGOLZA is an experimental treatment for severe hypertriglyceridemia, a condition characterized by high blood fat levels that can lead to acute pancreatitis. The slower-than-expected launch of TRYNGOLZA is due to the time needed to build prescription volumes as doctors adopt this new treatment method.\n\nThe report also highlights two other Ionis products: DAWNZERA, which treats hereditary angioedema, a rare genetic disorder that causes severe swelling attacks, and another drug in the pipeline. DAZZERA's sales have been steadily increasing, with $37 million in sales for the third quarter and $79 million year-to-date. Sales have been growing in each quarter since the drug's launch.\n\nIonis Pharmaceuticals is facing challenges due to the late-stage Phase III clinical trials, which are essential to confirm drug efficacy before regulatory approval. Two partnered programs' unfavorable trial results have forced Ionis to adjust its financial trajectory. Despite these setbacks, the company has preserved $1.9 billion in cash and investments. Ionis expects the timeline for its financial growth to shift from 2028 to 2029 due to the slower-than-anticipated TRYNGOLZA launch and the recent Phase III setbacks.\n\nTo balance investment and growth with operating discipline, Ionis is focusing on product expansion and mid-stage clinical trials. The company's growing portfolio of marketed medicines, a rich pipeline, and a capable team are driving multiple value drivers for continued growth. Ionis' Chief Development Officer, Holly Kordasiewicz, emphasizes that patient switches to DAZZERA, an expanding commercial team, and established partnerships will provide structural durability while management monitors prescriber conversion.",
  "summary": "Ionis's $1.9 billion cash pile buys time, but it is still to be seen whether patient switches to DAWNZERA can offset a slower TRYNGOLZA launch.",
  "key_points": [],
  "editors_take": "Delayed adoption of new treatments and clinical trial setbacks force the company to push its expected period of financial growth back by a full year.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Ionis: 3 Key Takeaways for Long-Term Investors",
        "url": "https://urgent.news/2026/11/10/ionis-3-key-takeaways-for-long-term-investors",
        "published": "2026-11-10T00:13:38.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}